Medically Reviewed and Compiled by Dr. Adam N. Khan, MD.
- Infant Vulnerability: Newborns have naturally low vitamin K levels at birth due to poor placental transfer, low vitamin K in breast milk, and an immature gut microbiome.
- Massive Prevention Impact: Standard newborn prophylaxis reduces the risk of late-onset vitamin K deficiency bleeding by 81-fold, nearly eliminating a condition that once caused widespread brain injury and death.
- Adult High-Risk Groups: While rare in healthy adults on typical diets, severe deficiency frequently develops in patients with malabsorption disorders, liver disease, chronic kidney disease, or prolonged antibiotic exposure.
EMERGENCY WARNING: Vitamin K Deficiency Bleeding (VKDB) in infants can occur suddenly and without prior warning signs. Seek immediate emergency medical care if an infant shows inexplicable bruising, bleeding from the nose or umbilical stump, pale or yellowed skin/eyes after 3 weeks, tarry black stools, persistent vomiting, extreme lethargy, or seizures. Half of all late VKDB cases involve life-threatening internal bleeding into the brain.
Understanding Vitamin K and Hemostasis
Vitamin K is a fat-soluble nutrient essential for blood coagulation and biological hemostasis. The body relies on vitamin K to synthesize essential clotting factors in the liver, specifically Factors II (prothrombin), VII, IX, and X, alongside regulatory proteins C and S. Without adequate vitamin K, these proteins cannot undergo gamma-carboxylation, leaving them functionally inactive as proteins induced by vitamin K absence or antagonism (PIVKA-II).
In human physiology, vitamin K exists primarily in two forms: phylloquinone (vitamin K1), abundant in leafy green vegetables, and menaquinones (vitamin K2), synthesized by gut flora and found in fermented foods. Because the body stores only minimal amounts of fat-soluble vitamin K compared to vitamins A or D, continuous supply and normal intestinal absorption are required to maintain healthy coagulation. When vitamin K stores drop, blood takes much longer to clot, creating a severe risk of spontaneous internal or external bleeding.
How Common Is Vitamin K Deficiency Bleeding?
Epidemiological surveillance data demonstrates a sharp contrast in how common vitamin K deficiency bleeding is between neonates and the adult population.
In newborns who do not receive preventive vitamin K at birth, early and classical VKDB occurs in 0.25% to 1.7% of live births (roughly 1 in 60 to 1 in 400 infants). Late-onset VKDB, which strikes between 1 week and 6 months of age, occurs at a rate of 4.4 to 10.5 per 100,000 live births in infants who skip prophylaxis. Epidemiological registries show that infants who do not receive the newborn vitamin K shot are 81 times more likely to develop severe bleeding than infants who receive the standard injection.
In adults, overt vitamin K deficiency bleeding is very rare in healthy individuals consuming a standard diet. However, functional vitamin K insufficiency is widespread, with nutritional surveillance data indicating that up to 55% of adults do not meet recommended daily intakes of phylloquinone. Severe clinical deficiency causing active hemorrhage in adults is almost exclusively confined to specific clinical populations with severe intestinal malabsorption, end-stage liver failure, chronic kidney disease, or long-term broad-spectrum antibiotic therapy.
Classification of Infant Vitamin K Deficiency Bleeding
Infant VKDB is classified into three clinical subtypes based on the timing of symptom onset:
- Early VKDB (First 24 Hours): Extremely rare in the general population but seen primarily in infants whose mothers took medications that interfere with vitamin K metabolism during pregnancy, such as anticonvulsants (phenytoin, carbamazepine) or anti-tuberculosis therapy (rifampin, isoniazid).
- Classical VKDB (Days 2 to 7): Occurs in 0.4% to 0.7% of unsupplemented newborns. It typically presents as gastrointestinal hemorrhage, umbilical cord bleeding, skin bruising, or bleeding following minor surgical procedures like circumcision.
- Late VKDB (Weeks 2 to 26): Occurs almost exclusively in breastfed infants who did not receive vitamin K prophylaxis at birth. Late VKDB carries the most severe prognosis: approximately 30% to 60% of affected infants suffer intracranial hemorrhage (bleeding inside the skull), leading to permanent neurological impairment or mortality in up to 20% of cases.
| VKDB Subtype | Onset Timing | Primary Risk Factors | Common Bleeding Sites | Incidence (Without Shot) |
| Early | First 24 hours of life | Maternal medications (anticonvulsants, rifampin) | Cephalohematoma, abdominal cavity | Rare overall; high in exposed |
| Classical | Day 2 to Day 7 | Delayed feeding, lack of prophylaxis | GI tract, umbilical stump, nose, skin | 0.25% – 1.7% of births |
| Late | Week 2 to Month 6 | Exclusive breastfeeding, no prophylaxis, cholestosis | Intracranial (brain), GI tract, skin | 4.4 – 10.5 per 100,000 births |
Unique Clinical Takeaways
Beyond standard lists of symptoms, clinical management of vitamin K dynamics reveals critical insights essential for patients, parents, and caregivers:
- Subclinical Cholestasis is a Silent Trigger for Late VKDB: Late-onset infant VKDB frequently presents in infants with undiagnosed, mild biliary atresia or neonatal hepatitis. Because bile salts are strictly required to absorb fat-soluble vitamin K, even minor liver or biliary dysfunction completely blocks oral absorption. In these infants, bleeding is often the very first clinical sign of underlying liver disease, making intramuscular prophylaxis life-saving.
- Antibiotic-Induced Dysbiosis Disrupts Adult Hemostasis: In hospitalized or elderly adults, broad-spectrum antibiotic courses lasting longer than 10 to 14 days destroy vitamin K2-producing anaerobic gut bacteria. When combined with reduced oral food intake during illness, coagulation factors can drop to dangerous levels within days, raising prothrombin time (PT/INR) without any underlying genetic blood disorder.
- Maternal Vitamin K Transfer is Physiologically Limited: Maternal dietary intake or high-dose oral supplementation during pregnancy does not significantly raise fetal vitamin K levels. The human placenta acts as a natural physiological barrier to fat-soluble vitamin K transfer. Consequently, newborn vitamin K reserves remain low regardless of maternal diet, rendering post-natal intramuscular supplementation necessary for all newborns.
Causes and Physiological Vulnerabilities
The high susceptibility of newborns to vitamin K deficiency stems from three distinct biological factors:
- Poor Placental Transfer: Lipophilic vitamin K crosses the placental barrier poorly, leaving newborns with plasma concentrations significantly lower than maternal levels.
- Sterile Newborn Gut: At birth, an infant’s gastrointestinal tract lacks the established bacterial microbiome (such as Bacteroides species) required to endogenously produce menaquinones (vitamin K2).
- Low Vitamin K Content in Breast Milk: Human breast milk is the ideal nutritional source for infants but naturally contains very low concentrations of vitamin K (typically 1 to 4 mcg/L), compared to fortified infant formula (which contains approximately 50 to 100 mcg/L).
In adults, deficiency stems from altered absorption, impaired utilization, or drug interactions. Chronic fat malabsorption conditions—including celiac disease, Crohn’s disease, cystic fibrosis, short bowel syndrome, and exocrine pancreatic insufficiency—prevent the micellar solubilization of fat-soluble vitamins. Furthermore, severe parenchymal liver disease impairs the hepatic synthesis of functional clotting factors even when vitamin K intake is adequate.
Diagnosis and Laboratory Monitoring
Diagnosing vitamin K deficiency involves clinical evaluation alongside specialized coagulation testing:
- Prothrombin Time (PT) and International Normalized Ratio (INR): PT measures the extrinsic and common pathways of the coagulation cascade. Prolongation of PT/INR is the primary laboratory hallmark of functional vitamin K deficiency.
- Activated Partial Thromboplastin Time (aPTT): aPTT measures the intrinsic pathway and may also be prolonged in severe deficiency states.
- Undercarboxylated Prothrombin (PIVKA-II): Direct measurement of uncarboxylated prothrombin serves as a highly sensitive biomarker for subclinical vitamin K depletion, rising before significant PT prolongation occurs.
- Response to Parenteral Vitamin K: A rapid normalization of PT/INR within 12 to 24 hours following intravenous or subcutaneous administration of phytonadione confirms the diagnosis and distinguishes vitamin K deficiency from end-stage liver failure or disseminated intravascular coagulation (DIC).
Prevention and Clinical Management
Universal prophylaxis administered shortly after birth remains the primary public health strategy to prevent infant VKDB.
The American Academy of Pediatrics (AAP) and global health organizations recommend a single intramuscular injection of 0.5 mg to 1.0 mg of phytonadione (vitamin K1) for all newborns within 6 hours of birth. Intramuscular administration creates a slow-release tissue depot in the skeletal muscle that sustains adequate vitamin K levels across the first several months of life until gut colonization and dietary diversification occur.
While oral vitamin K regimens are utilized in some countries, clinical studies show that oral dosing is substantially less effective than intramuscular administration at preventing late VKDB. Oral regimens require multiple precisely timed doses and fail to protect infants who experience undetected malabsorption or acute infantile vomiting.
For adults diagnosed with dietary or malabsorption-related vitamin K deficiency, treatment involves oral or parenteral phytonadione supplementation, alongside addressing the underlying gastrointestinal or hepatic disease. Patients taking vitamin K antagonist anticoagulants (such as warfarin) require careful dietary monitoring to maintain stable systemic coagulation levels.
FAQs
Newborns are born with very low stores of vitamin K because little passes through the placenta, their guts lack vitamin K-producing bacteria, and human breast milk naturally contains low levels of the vitamin.
No. Vitamin K transfers poorly across the placenta regardless of maternal diet or oral supplements, making direct post-birth supplementation necessary to protect the baby.
Key warning signs include unexplained skin bruising, bleeding from the nose or umbilical cord, dark tarry stools, pale or yellowed eyes/skin after 3 weeks, persistent vomiting, and severe lethargy or seizures.
Yes. Extensive research over six decades confirms that the newborn intramuscular vitamin K shot is extremely safe, highly effective, and carries no proven link to childhood cancer or leukemia.
Adult vitamin K deficiency is treated with oral or injectable phytonadione (vitamin K1) supplements, along with treating underlying malabsorption or dietary causes.
Author and Reviewer Information
Reviewer Bio: Dr. Adam N. Khan, M.D., earned his medical degree from King Edward Medical University and completed his Internal Medicine residency at Mayo Hospital. He is an active PMDC-licensed physician dedicated to global health literacy, translating complex peer-reviewed research into accurate, safe, and actionable health guidance for MEDLIFEGUIDE readers.
Affiliation & Conflict Disclosure: Dr. Adam N. Khan serves as an independent medical reviewer for MEDLIFEGUIDE. He reports no relevant financial conflicts of interest, commercial affiliations, or pharmaceutical relationships related to the content of this article.